The Pharmaceutical Journal
Vol 280 No 7501 p560
10 May 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Potential metastatic cancer strategy

Combination of bortezomib with MD5-1 — a tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist monoclonal antibody — could be a useful strategy for treating metastatic solid tumours, the authors of a new study suggest (Journal of the National Cancer Institute, 29 April 2008).

Mice given the combination treatment had fewer lung metastases after 18 days and survived for longer than those given either agent alone, without obvious signs of toxicity.